10 results about "Intestinal epithelium" patented technology

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

The application discloses a brain hemorrhage prognosis improvement method based on intestinal flora regulation and relates to the technical field of intestinal microecology.The application comprises the following steps: detecting feces, starting intervention if the enterococcus abundance and neuroinflammatory metabolic markers exceed the standard, stopping the use of conventional nutrient solution, perfusing a special component containing sugar analogs, blocking the energy uptake of enterococcus, simultaneously providing a carbon source for beneficial bacteria, synchronously perfusing a microsphere suspension containing a molecular capture function, adsorbing and fixing proinflammatory metabolic waste in the intestinal tract, blocking the blood entry of the proinflammatory metabolic waste, perfusing live bacteria with different functions three times in time sequence, sequentially completing the acidification of the environment, constructing a bacterial membrane barrier and repairing the intestinal epithelium, and re-detecting after each round of intervention, selecting the maintenance period or adjusting the intensity and then recycling according to the decrease of enterococcus and markers.The application can limit the competitive advantage of enterococcus in the utilization of carbon sources after brain hemorrhage by sequentially implementing competitive inhibition of the phosphotransferase system and multi-species ecological niche occupation.

To provide a composition that can suppress the decline in the barrier function of the intestinal epithelium in non-infectious inflammatory bowel disease. [Solution] An agent containing human milk oligosaccharides that suppresses the decline in the barrier function of the intestinal epithelium in non-infectious inflammatory bowel disease.

To provide excellent intestinal epithelial-like cells expressing drug-metabolizing enzymes and drug transporters applicable for pharmacokinetic assessment, more specifically, intestinal epithelial-like cells having properties closer to those of primary cultured human intestinal epithelial cells that are difficult to obtain, and to provide production methods thereof.SOLUTION: The present invention is characterized by the monolayer culturing of organoid-derived cells. As a result of analyzing the obtained monolayer film, drug-metabolizing enzymes (each CYP) and drug transporters (PEPT1, MDR1), and the like possessed by small intestinal epithelial cells were expressed and excellent intestinal epithelial-like cells that also have a tight junction function were obtained. From the above, intestinal epithelial-like cells that can be used for pharmacokinetic evaluation and / or drug toxicity evaluation can be efficiently produced.SELECTED DRAWING: Figure 1

本发明属于生物医药与营养学技术领域，具体涉及一种母乳低聚糖在制备改善衰老肠道稳态的产品中的应用。本发明发现不同结构HMOs对衰老小鼠肠上皮稳态的作用不同，3'‑SL和LNnT能更好地促进衰老小鼠肠道屏障及ISCs功能恢复，维持肠上皮稳态。抗生素实验证明HMOs对衰老小鼠肠上皮稳态的有益作用需要肠道微生物群的参与。16S rDNA测序表明3'‑SL和LNnT可重塑肠道微生物群结构。代谢组学分析显示，3'‑SL主要影响能量代谢、氨基酸代谢通路；LNnT主要影响bile secretion,tryptophan metabolism,and phenylalanine metabolism通路。

While studies have been made on a method of selectively inducing differentiation from pluripotent stem cells into enterocyte-like cells, provided is an excellent and high-functionality enterocyte-like cell population that can be stably tested for multi-drug metabolism and permeability, and also provided an efficient method of producing cells. The method of inducing differentiation from pluripotent stem cells into enterocyte-like cells includes the following steps (1) and (2): (1) a step of inducing differentiation from pluripotent stem cells into definitive endoderm cells; and (2) a step of culturing the definitive endoderm cells in a system containing CHIR99021, followed by induction of differentiation into intestinal progenitor cells. A cell population of enterocyte-like cells is more effectively obtained by seeding and culturing enterocyte-like cells produced by the method of inducing differentiation, in a base material for organoid production or a base material for two-dimensional culture.

Peptide fragments of Amuc_1100* and uses thereof are disclosed. The peptides are shown to be ligands that activate TLR2 and are useful in the treatment of obesity and related diseases or disorders. The peptides of the invention are further useful in the treatment of small intestinal cancer, in the promotion of immune responses, and in intestinal epithelial barrier dysfunction.

The application belongs to the technical field of biological medicine and intestinal development regulation, and particularly relates to application of rubixanthin in preparation of a preparation for improving abnormal intestinal development of offspring caused by gestational diabetes. It is found for the first time that the level of rubixanthin in the intestine of offspring under the condition of gestational diabetes is significantly decreased, and the decrease is closely related to intestinal epithelial dysplasia. Animal experiments and function verification show that supplement of rubixanthin can significantly improve abnormal intestinal development of offspring of gestational diabetes, promote intestinal crypt cell proliferation and differentiation, and restore the structure and function of intestinal epithelial barrier. The rubixanthin can be used for preparing a medicine, a nutritional preparation or a dietary supplement, and is suitable for improving or preventing intestinal epithelial dysplasia, abnormal digestive function and related metabolic risks of offspring related to gestational diabetes. The application provides a safe, effective and targeted new intervention approach for abnormal intestinal development of offspring of gestational diabetes, and has a good application prospect.

This invention provides the use and products of L-glutamine in the treatment or prevention of intestinal barrier dysfunction, belonging to the field of pharmaceutical technology. An animal model was established using the tail suspension method to simulate a microgravity environment to induce intestinal barrier dysfunction, demonstrating that L-glutamine can significantly improve intestinal barrier function. Its beneficial effects include upregulating the expression of tight junction proteins Claudin-1, Occludin, and ZO-1 in intestinal tissue, directly repairing the intestinal epithelial physical barrier; and downregulating the expression of NF-κB p65 protein, inhibiting NF-κB signaling pathway-related inflammatory responses. Furthermore, the application of L-glutamine can alleviate liver pathological changes secondary to intestinal barrier dysfunction. This invention provides a novel nutritional intervention strategy for the repair of intestinal barrier dysfunction. The product can be an oral pharmaceutical preparation or a special medical purpose food, and is safe, effective, and has significant application prospects.

This invention discloses the application of hemp seed oil in the preparation of drugs for the prevention or mitigation of acute ionizing radiation-induced diseases, relating to the field of biomedical technology. This invention discovers that hemp seed oil can protect the intestinal epithelium and crypt structures under acute high-dose irradiation, maintaining the intestinal barrier and digestive function. Simultaneously, it can protect splenic immune function by slowing the reduction in the white pulp region of the spleen and increasing the number of nucleated cells and lymphoid immune cells in the spleen, thereby significantly improving the individual survival rate after lethal doses of radiation, providing a new approach for treating acute ionizing radiation-induced diseases.